A resurgence of interest in psychedelics has come to the forefront as researchers look to create alternative treatment solutions for a growing patient base. In the last few years alone, classic psychedelics have shown the potential to provide an improved, alternative treatment solution to a vast array of mental health indications — from treatment-resistant depression and anxiety to PTSD. Building on these promising results, these compounds need to be modified to generate fewer side effects, better efficacy and out-of-clinic applicability. Is it possible to utilize psychedelics to develop drugs that are more accessible to the mainstream patient base? MagicMed Industries certainly thinks so. The Canadian company has made its mission to support and enable the commercialization of psychedelic-derived pharmaceuticals for brain and mental health.